Global Attention deficit Hyperactivity Disorder (ADHD) Drugs Market Report 2019-2023 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 28, 2019--
The “Global Attention deficit Hyperactivity Disorder (ADHD) Drugs Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.
The attention deficit hyperactivity disorder (ADHD) drugs market will register a CAGR of almost 6% by 2023.
The rising incidence rate of ADHD among children is one of the critical factors that will trigger the growth of the attention deficit hyperactivity disorder drugs market. The expansion of the patient pool with positive ADHD symptoms is fueling the demand for ADHD therapies. As per the CDC, in 2016. Approximately 9.4% of children aged 2-17 years were diagnosed with ADHD. Thus, a significant patient pool (aged between 12 and 17 years) rely on medications. This is expected to rise further with the increasing prevalence of the disease, thereby contributing to the growth of the market during the forecast period.
Rising government support
The global ADHD drugs market is currently witnessing an increase in the number of government initiatives to promote the awareness of the disease and to fund drug development in the area of mental health therapeutics. Additionally, the Centers for Disease Control and Prevention (CDC) supports the National Resource Center (NRC) on ADHD, a program designed to help children and adults with ADHD. The NRC program provides information, resources, and advice to parents on how to help their children with ADHD. Thus, the rising government support to help people with ADHD is expected to drive the growth of the market during the forecast period.
Lack of patient compliance with ADHD treatment
The pharmacological (medications) treatment with neuro-stimulant drugs is considered as the gold standard for the treatment of ADHD in children and adults. However, the multiple dosing regimens associated with neuro-stimulant drugs, such as methylphenidate and amphetamine, and the timely dosing and long duration of the treatment are leading to a decrease in the patient compliance with these drugs. This leads to a decline in the consumption of ADHD drugs, thereby impeding the growth of the market.
The market appears to be highly fragmented. The presence of several companies, including Johnson & Johnson Services Inc. and NEOS Therapeutics Inc. makes the competitive environment quite intense. Factors such as the rising incidence rate of ADHD among children and the increasing government support will provide considerable growth opportunities to attention deficit hyperactivity disorder drugs manufactures. Amneal Pharmaceuticals Inc., Eli Lilly and Co., and Takeda Pharmaceutical Co. Ltd. are some of the major companies covered in this report.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market segmentation analysis
PART 04: MARKET SIZING
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
PART 06: MARKET SEGMENTATION BY PRODUCT
Market segmentation by product
Comparison by product
Stimulants - Market size and forecast 2018-2023
Non-stimulants - Market size and forecast 2018-2023
Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Key leading countries
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
Market positioning of vendors
- Amneal Pharmaceuticals Inc.
- Eli Lilly and Co.
- Johnson & Johnson Services Inc.
- NEOS Therapeutics Inc.
- Takeda Pharmaceutical Co. Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/adaglh
View source version on businesswire.com:https://www.businesswire.com/news/home/20190528005654/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Mental Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 05/28/2019 01:05 PM/DISC: 05/28/2019 01:05 PM